与全科医生合作优化淋巴瘤患者生存期照护:GOSPEL I 二期随机对照试验
GOSPEL I 是由护士实施、预先设定的共享照护路径,由癌症中心专科医生与社区全科医生共同承担随访职责。主要评估可行性及患者报告结局,包括健康相关生活质量、照护体验、症状困扰、合并症负担、饮食摄入、体力活动、经济困扰和照护满意度,并分析安全性和过程指标,为后续更大规模确定性试验提供依据。
要点
- GOSPEL I 为护士实施的共享照护路径,由血液科医生、专科护士与全科医生共同承担淋巴瘤随访。
- 主要评估可行性及患者报告结局,包括生活质量、照护体验、症状困扰和经济困扰等。
核心结论
- 本试验旨在探索淋巴瘤幸存者共享照护新模式的可行性和可接受性,为后续更大规模确定性试验提供依据。
研究设计与样本
- 干预组接受 GOSPEL I 护士实施的共享随访照护,对照组接受常规专科主导随访。
关键数值与推荐
- GOSPEL I 为护士实施、预先设定的共享照护路径,随访职责由癌症中心专科医生和全科医生共同承担。
- 评估指标包括可行性、健康相关生活质量(FACT-Lym)、照护体验、症状困扰、合并症负担、饮食摄入、体力活动、经济困扰和照护满意度。
- 安全性指标包括住院和计划外淋巴瘤门诊就诊,过程指标包括干预保真度和经济指标。
临床怎么用
- 该研究为方案阶段,尚未报告共享照护模式对淋巴瘤幸存者结局的实际效果。
局限性
- 本文为试验方案,尚无结果数据,可行性及患者报告结局尚待验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival rates for lymphoma are highest amongst hematological malignancies. In 2019, it was estimated that over 6400 Australians were diagnosed with lymphoma, a group of hematological malignancies with a high 5-year survival rate of ~ 76%. There is an increased focus on the promotion of wellness in survivorship and active approaches to reducing morbidity related to treatment; however, current models of follow-up care heavily rely on hospital-based specialist-led care. Maximizing the potential of general practitioners (GPs) in the ongoing management of cancer is consistent with the national health reform principles and the Cancer Council Australia's Optimal Care Pathways. GPs are well positioned to provide guideline-based follow-up care and are more likely to address comorbidities and psychosocial issues and promote healthy lifestyle behaviors. This study aims to test the feasibility of the GOSPEL I intervention for implementing an integrated, shared care model in which cancer center specialists and community-based GPs collaborate to provide survivorship care for patients with lymphoma. METHODS: We describe a protocol for a phase II, randomized controlled trial with two parallel arms and a 1:1 allocation. Sixty patients with Hodgkin's and non-Hodgkin's lymphoma will be randomized to usual specialist-led follow-up care (as determined by the treating hematologists) or a shared follow-up care intervention (i.e., GOSPEL I). GOSPEL I is a nurse-enabled, pre-specified shared care pathway with follow-up responsibilities shared between cancer center specialists (i.e., hematologists and specialist cancer nurses) and GPs. Outcome measures assess feasibility as well as a range of patient-reported outcomes including health-related quality of life as measured by the Functional Assessment of Cancer Therapy-Lymphoma, patient experience of care, symptom distress, comorbidity burden, dietary intake, physical activity behaviors, financial distress/interference, and satisfaction of care. Safety indicators including hospital admission and unscheduled lymphoma clinic visits as well as process outcomes such as intervention fidelity and economic indicators will be analyzed. DISCUSSION: This trial is designed to explore the feasibility and acceptability of a new model of shared care for lymphoma survivors. Patient-reported outcomes as well as potential barriers to implementation will be analyzed to inform a larger definitive clinical trial testing the effects and implementation of a shared care model on health-related quality of life of lymphoma survivors. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Registry ACTRN12620000594921 . Registered on 22 May 2020.
引用
- Chan RJ, Buhagiar S, Teleni L, et al. Partnering with general practitioners to optimize survivorship for patients with lymphoma: a phase II randomized controlled trial (the GOSPEL I trial). Trials. 2021. PMID: 33407797. doi:10.1186/s13063-020-04945-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。